Do mild-to-moderate elevations in ALT and AST indicate MASLD and hepatic insulin resistance?

Metabolic-associated steatotic liver disease (MASLD) has become the most common cause of chronic liver disease globally, and its clinical presentation is frequently characterized by mild-to-moderate elevations in serum transaminases.

Clinical and diagnostic evidence

Mildly elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels—typically defined as less than 2–3 times the upper limit of normal—are the primary biochemical indicators of MASLD in Western populations.

• Prevalence and association: MASLD affects roughly 25% of the general population and up to 70% of individuals with obesity or type 2 diabetes. It is the leading cause of unexplained mild transaminase elevations in these cohorts.
• Sensitivity vs. specificity: While these elevations are a hallmark of the disease, they are not perfectly sensitive. Up to 80% of patients with advanced fibrosis may present with transaminase levels in the normal or only mildly elevated range.
• Risk stratification: Major clinical guidelines (AASLD, EASL) emphasize that while transaminases signal potential MASLD, they do not accurately predict the stage of fibrosis. Practitioners should utilize non-invasive tests like the FIB-4 index to further assess liver health in at-risk patients.

Mechanistic link to insulin resistance

Serum ALT and AST serve as functional biomarkers for hepatic insulin resistance (IR), reflecting both metabolic flux and cellular stress.

• Gluconeogenic flux: ALT is a key enzyme in gluconeogenesis, converting alanine into pyruvate. In a healthy state, insulin suppresses this process; however, in hepatic IR, this suppression fails, and ALT activity is often upregulated to support increased glucose production.
• Lipogenesis and injury: Hepatic IR drives de novo lipogenesis, leading to the accumulation of intrahepatic triglycerides (steatosis). This lipid accumulation triggers oxidative stress and inflammatory pathways, causing hepatocyte damage and the subsequent leakage of AST and ALT into the bloodstream.
• Predictive value: Research indicates that the ALT/AST ratio is a significant predictor of HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) scores, often providing higher predictive accuracy for insulin resistance than ALT alone, even after adjusting for body mass index.

Bottom line

Mild-to-moderate elevations in ALT and AST are common indicators of MASLD and correlate strongly with hepatic insulin resistance. These enzymes reflect the underlying failure of insulin to regulate hepatic glucose and lipid metabolism, though they must be interpreted within the broader context of metabolic risk factors and validated fibrosis scores.